Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$127.16+2.49 (+2.00%)
Close on Nov 18, 2026Market cap $8.23BP/E 123.5Yield –
Protagonist Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Protagonist Therapeutics's operating income for the twelve months ending Jun 30, 2026 was $58.34M, up 143.3% year over year. For fiscal 2025 it was -$158.13M, down 162.5% from the year before. The highest annual figure on record is $252.84M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$158.13M | -162.5% |
| FY2024 | Dec 31, 2024 | $252.84M | – |
| FY2023 | Dec 31, 2023 | -$93.65M | – |
| FY2022 | Dec 31, 2022 | -$131.37M | – |
| FY2021 | Dec 31, 2021 | -$125.85M | – |
| FY2020 | Dec 31, 2020 | -$64.52M | – |
| FY2019 | Dec 31, 2019 | -$80.52M | – |
| FY2018 | Dec 31, 2018 | -$42.27M | – |
| FY2017 | Dec 31, 2017 | -$37.90M | – |
| FY2016 | Dec 31, 2016 | -$32.67M | – |
| FY2015 | Dec 31, 2015 | -$14.79M | – |
| FY2014 | Dec 31, 2014 | -$9.32M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $158.77M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.65M | – |
| Q4 FY2025 | Dec 31, 2025 | -$50.36M | -139.7% |
| Q3 FY2025 | Sep 30, 2025 | -$46.42M | – |
| Q2 FY2025 | Jun 30, 2025 | -$42.04M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.31M | -109.4% |
| Q4 FY2024 | Dec 31, 2024 | $126.78M | +450.0% |
| Q3 FY2024 | Sep 30, 2024 | -$41.45M | – |
| Q2 FY2024 | Jun 30, 2024 | -$38.79M | – |
| Q1 FY2024 | Mar 31, 2024 | $206.31M | – |
| Q4 FY2023 | Dec 31, 2023 | $23.05M | – |
| Q3 FY2023 | Sep 30, 2023 | -$38.33M | – |
| Q2 FY2023 | Jun 30, 2023 | -$42.35M | – |
| Q1 FY2023 | Mar 31, 2023 | -$36.02M | – |
| Q4 FY2022 | Dec 31, 2022 | -$36.52M | – |
| Q3 FY2022 | Sep 30, 2022 | -$32.30M | – |
| Q2 FY2022 | Jun 30, 2022 | -$41.44M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.11M | – |
| Q4 FY2021 | Dec 31, 2021 | -$37.02M | – |
| Q3 FY2021 | Sep 30, 2021 | -$33.93M | – |
| Q2 FY2021 | Jun 30, 2021 | -$30.88M | – |
| Q1 FY2021 | Mar 31, 2021 | -$24.02M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.83M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.77M | – |
| Q2 FY2020 | Jun 30, 2020 | -$18.22M | – |
| Q1 FY2020 | Mar 31, 2020 | -$19.70M | – |
| Q4 FY2019 | Dec 31, 2019 | -$17.30M | – |
| Q3 FY2019 | Sep 30, 2019 | -$17.17M | – |
| Q2 FY2019 | Jun 30, 2019 | -$31.41M | – |
| Q1 FY2019 | Mar 31, 2019 | -$14.65M | – |
| Q4 FY2018 | Dec 31, 2018 | -$15.41M | – |
| Q3 FY2018 | Sep 30, 2018 | -$9.39M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.24M | – |
| Q1 FY2018 | Mar 31, 2018 | -$8.23M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.51M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.98M | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.13M | – |
| Q1 FY2017 | Mar 31, 2017 | -$14.27M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.40M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.14M | – |
See a number that looks wrong?